RxDoctor Payments DataLook up a doctor →

Mahesh Raju, MD

Interventional Cardiology · Downers Grove, ILNPI 1811143548

Payments from drug & device makers

$462,084in general payments, 2019–2025

Across 1,059 payments — averaging $436.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • M.a. Med Alliance S.A.$113K
  • Johnson & Johnson$100K
  • Boston Scientific$79K
  • Shockwave Medical, Inc$53K
  • Janssen Research & Development, LLC$30K
  • Medtronic$15K
  • plus $72K from 45 others

What the payments were for

  • Consulting fees$39,96914%
  • Speaking & faculty fees$167,74060%
  • Grants$1,1230%
  • Travel & lodging$31,20111%
  • Food & beverage$40,14314%
  • Education$370%
  • Entertainment$4480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462,084 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$262,666
Medicare patients
729
Services billed
1,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban108$108,621
EliquisApixaban89$83,858
EntrestoSacubitril/Valsartan28$36,885
NexlizetBempedoic Acid/Ezetimibe12$6,444
Atorvastatin Calcium388$3,925
Metoprolol Succinate203$3,162
ClopidogrelClopidogrel Bisulfate250$2,490
Rosuvastatin Calcium128$1,887
Amlodipine Besylate162$1,379
Lisinopril126$1,054
Metoprolol Tartrate156$1,004
Carvedilol114$1,002
Ezetimibe37$974
Losartan Potassium96$899
Warfarin Sodium37$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$100,425$108,621108 claims
PfizerEliquis$24$83,85889 claims
NovartisEntresto$39$36,88528 claims
Esperion Therapeutics, Inc.Nexlizet$136$6,44412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Downers Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →